Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

31 Aug 2018

Abstract excerpt

Purpose TP53 mutation (MT) in epidermal growth factor receptor ( EGFR) -MT non–small cell lung cancer (NSCLC) is associated with poor response to targeted therapy; however, its impact on survival is not clearly established. Patients and Methods We performed an analysis of patients with stage IV EGFR MT NSCLC with available gene sequencing data. Associations between baseline characteristics; molecular profile,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30766968
DOI: 10.1200/po.18.00107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung CancerPMID 30766968Read ↗

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIsSemantic proximity Read ↗

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinibSemantic proximity Read ↗

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.Semantic proximity Read ↗

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.Semantic proximity Read ↗

[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.Semantic proximity Read ↗

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study.Semantic proximity Read ↗

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort.Semantic proximity Read ↗

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.